期刊
PHARMACEUTICS
卷 14, 期 1, 页码 -出版社
MDPI
DOI: 10.3390/pharmaceutics14010124
关键词
glioblastoma; local treatment; hyaluronic acid; polymer-drug conjugates; bio-responsive linkers
资金
- European Union [887609]
- Fonds de la Recherche Scientifique-Fonds National de la Recherche Scien-tifique (FRS-FNRS) [40000747]
- China Scholarship Council (CSC)
- Televie (Belgium)
- FRS-FNRS [33669945, 40003419]
- Marie Curie Actions (MSCA) [887609] Funding Source: Marie Curie Actions (MSCA)
This study evaluated the feasibility of using hyaluronic acid (HA) for the local treatment of glioblastoma. The results demonstrate that HA-Hz-DOX showed the best performance in killing GBM cells both in vitro and in vivo, highlighting the potential of hyaluronic acid as a polymeric platform.
Glioblastoma is an unmet clinical need. Local treatment strategies offer advantages, such as the possibility to bypass the blood-brain barrier, achieving high drug concentrations at the glioblastoma site, and consequently reducing systemic toxicity. In this study, we evaluated the feasibility of using hyaluronic acid (HA) for the local treatment of glioblastoma. HA was conjugated to doxorubicin (DOX) with distinct bio-responsive linkers (direct amide conjugation HA-NH-DOX), direct hydrazone conjugation (HA-Hz-DOX), and adipic hydrazone (HA-AdpHz-DOX). All HA-DOX conjugates displayed a small size (less than 30 nm), suitable for brain diffusion. HA-Hz-DOX showed the best performance in killing GBM cells in both 2D and 3D in vitro models and displayed superior activity in a subcutaneous GL261 tumor model in vivo compared to free DOX and other HA-DOX conjugates. Altogether, these results demonstrate the feasibility of HA as a polymeric platform for the local treatment of glioblastoma and the importance of rationally designing conjugates.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据